Cancer News and Research

Latest Cancer News and Research

The PLAN for stroke prognosis

Researchers have developed a new prediction rule, which they say predicts both short-term and 1-year mortality after acute ischemic stroke.

29 Oct 2012

Low-dose radiation PCT developed for breast screening

US researchers have developed a high-resolution, low-dose phase contrast X-ray tomography for diagnosis of breast cancers that delivers a 74% reduced radiation dose compared with conventional PCT.

29 Oct 2012

Aspirin improves colorectal cancer survival in tandem with gene mutation

Aspirin significantly improves survival in colorectal cancer patients who have a mutation in a carcinogenesis-associated signaling pathway, the results of a US and Japanese study indicate.

29 Oct 2012

Positive interim data from XBiotech monoclonal antibody Phase II study for type 2 diabetes

XBiotech, a privately held biotechnology company, announced positive interim analysis results today from a Phase II study using a True Human monoclonal antibody (MABp1) in patients with type 2 diabetes. Results from this study continue to reinforce the role of IL-1α as a master regulator of chronic inflammation in multiple disease states, and the therapeutic benefits of neutralizing antibodies produced from the XBiotech platform.

29 Oct 2012

Antidepressant doxepin eases pain associated with oral mucositis

An oral rinse of the antidepressant doxepin significantly eased pain associated with oral mucositis in patients receiving radiation therapy for cancers of the head and neck, a study led by Mayo Clinic found. The findings were presented at the American Society for Radiation Oncology annual meeting in Boston.

29 Oct 2012

Scientists decode epigenetic programming of three virulent forms of acute lymphoblastic leukemia

A team of national and international researchers, led by Weill Cornell Medical College scientists, have decoded the key "software" instructions that drive three of the most virulent forms of acute lymphoblastic leukemia (ALL). They discovered ALL's "software" is encoded with epigenetic marks, chemical modifications of DNA and surrounding proteins, allowing the research team to identify new potential biomarkers and therapeutic targets.

29 Oct 2012

Ultra-high performance SPECT systems announced by MILabs

MILabs, B.V. the Netherlands‐based innovator and manufacturer of pre‐clinical SPECT/PET/CT imaging devices announces the release of the Plus! Systems: the U‐SPECT+ and U‐SPECT+ /CT.

29 Oct 2012

New prostate cancer therapy triggers questions about cost, effectiveness and safety

Because proton therapy can be targeted much more precisely, it should minimize any damage to sensitive nerves and tissue around the prostate.

29 Oct 2012

Isis commences ISIS-FXIRx Phase 2 study in knee replacement surgery patients

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 2 comparator-controlled study evaluating ISIS-FXIRx in patients undergoing knee replacement surgery, also referred to as total knee arthroplasty (TKA).

29 Oct 2012

Botanical treatment holds hope for triple-negative breast cancer

A unique formula made from medicinal mushrooms, traditional Chinese herbs and other natural ingredients inhibits aggressive, human triple-negative breast cancer and breast-to-lung metastasis in mice. This is the third peer-reviewed study to demonstrate the botanical formula's anticancer effects.

29 Oct 2012

AstraZeneca commences FASLODEX Phase III study for hormone receptor-positive metastatic breast cancer

AstraZeneca today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy. The Phase III study is designed to evaluate the efficacy and tolerability of fulvestrant 500 mg compared to anastrozole 1 mg in this patient population.

29 Oct 2012

Nonclinical data on Provectus PV-10 oncology drug presented at 27th SITC

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, presented nonclinical data on PV-10 at the Society for Immunotherapy of Cancer (SITC) 27th Annual Meeting on October 26 and 27, 2012 in North Bethesda, MD.

29 Oct 2012

Cellectis announces successful programming of immune system cells to kill cancer cells

Cellectis, the genome engineering specialist, has announced successfully programming cells from the immune system (T cells) to kill cancer cells. This technological breakthrough was revealed for the first time ever on Saturday, October 27th at the congress of the ESGCT (European Society of Gene & Cell Therapy) in Versailles, outside Paris.

29 Oct 2012

Tumor count in the breast an important consideration for providing radiation therapy

Not all women diagnosed with operable breast cancer present with a single tumor; some have multifocal disease appear in the breast, which means multiple tumors found in the same breast quadrant, while others have multicentric disease, where multiple tumors are found in separate breast quadrants. Multifocal or multicentric disease is not a standard indication to receive radiation after mastectomy. For patients who undergo lumpectomy, radiation dose and extent is not altered based on multifocal or multicentric disease compared to patients presenting with a single tumor.

29 Oct 2012

Living examples of hope and determination against cancer

Their battle with cancer is not the only thing that unites the Labrada sisters of Houston who are now cancer-free and strong advocates for women taking charge of their bodies.

29 Oct 2012

Alternate method to precisely tag breast cancer tumors

When surgeons operate to remove a tumor, determining exactly where to cut can be tricky. Ideally, the entire tumor should be removed while leaving a continuous layer of healthy tissue, but current techniques for locating the tumors during surgery are imprecise. Now a multidisciplinary team from the University of California, San Diego, is developing an alternate means of precisely tagging breast cancer tumors for removal or targeted destruction.

29 Oct 2012

Improvements in rare cell isolation and common blood tests

At the Sixteenth International Conference on Miniaturized Systems for Chemistry and Life Sciences (microTAS) to be held Oct. 28-Nov. 1, in Okinawa, Japan, University of Cincinnati researchers will present four papers, including one detailing improvements in rare cell isolation and one detailing improvements, in terms of cost and time, of common blood tests.

29 Oct 2012

Female smokers who stop before middle age on average gain ten extra years of life

The largest-ever study of the hazards of smoking and benefits of stopping for women in the UK has shown that female smokers lose at least ten years of lifespan, but that stopping before the age of 40, and preferably well before the age of 40, avoids more than 90% of the increased risk of dying caused by continuing to smoke, while stopping before the age of 30 avoids over 97% of it.

29 Oct 2012

First Edition: October 29, 2012

Today's headlines include reports about how the presidential election's outcome could impact the insurance industry as well as the fate of people who are sick or uninsured.

29 Oct 2012

GTx to continue enobosarm Phase III trials for muscle wasting in patients with NSCLC

GTx, Inc. today announced that a per protocol interim safety review on Friday, October 26, 2012, by an independent Data Safety Monitoring Board (DSMB) recommended that GTx continue clinical development as planned with its two pivotal Phase III trials of enobosarm (GTx-024) for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer.

29 Oct 2012

Cancer News and Research

Latest Cancer News and Research

The PLAN for stroke prognosis

Low-dose radiation PCT developed for breast screening

Aspirin improves colorectal cancer survival in tandem with gene mutation

Positive interim data from XBiotech monoclonal antibody Phase II study for type 2 diabetes

Antidepressant doxepin eases pain associated with oral mucositis

Scientists decode epigenetic programming of three virulent forms of acute lymphoblastic leukemia

Ultra-high performance SPECT systems announced by MILabs

New prostate cancer therapy triggers questions about cost, effectiveness and safety

Isis commences ISIS-FXIRx Phase 2 study in knee replacement surgery patients

Botanical treatment holds hope for triple-negative breast cancer

AstraZeneca commences FASLODEX Phase III study for hormone receptor-positive metastatic breast cancer

Nonclinical data on Provectus PV-10 oncology drug presented at 27th SITC

Cellectis announces successful programming of immune system cells to kill cancer cells

Tumor count in the breast an important consideration for providing radiation therapy

Living examples of hope and determination against cancer

Alternate method to precisely tag breast cancer tumors

Improvements in rare cell isolation and common blood tests

Female smokers who stop before middle age on average gain ten extra years of life

First Edition: October 29, 2012

GTx to continue enobosarm Phase III trials for muscle wasting in patients with NSCLC

Industry Focus eBook - Oncology (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in